HDAC6 and primary cutaneous T-cell non-Hodgkin lymphoma: In contrast, HDAC6 expression showed a significant beneficial influence on survival [P = 0.04, hazard ratio (HR) 0.39, 95% confidence interval 0.16, 0.96] independent of the CTCL subtype.